Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
INZY logo INZY
Upturn stock ratingUpturn stock rating
INZY logo

Inozyme Pharma Inc (INZY)

Upturn stock ratingUpturn stock rating
$4
Last Close (24-hour delay)
Profit since last BUY168.46%
upturn advisory
Consider higher Upturn Star rating
BUY since 41 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/02/2025: INZY (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $4

1 Year Target Price $4

Analysts Price Target For last 52 week
$4 Target price
52w Low $0.72
Current$4
52w High $6.24

Analysis of Past Performance

Type Stock
Historic Profit 50.55%
Avg. Invested days 26
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/02/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 258.25M USD
Price to earnings Ratio -
1Y Target Price 4
Price to earnings Ratio -
1Y Target Price 4
Volume (30-day avg) 7
Beta 2.29
52 Weeks Range 0.72 - 6.24
Updated Date 07/8/2025
52 Weeks Range 0.72 - 6.24
Updated Date 07/8/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.68

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -48.45%
Return on Equity (TTM) -141.69%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 220425296
Price to Sales(TTM) -
Enterprise Value 220425296
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -4.25
Shares Outstanding 64561800
Shares Floating 29983802
Shares Outstanding 64561800
Shares Floating 29983802
Percent Insiders 1.26
Percent Institutions 94.29

ai summary icon Upturn AI SWOT

Inozyme Pharma Inc

stock logo

Company Overview

overview logo History and Background

Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases associated with ENPP1 and NT5E deficiencies. Founded in 2015, it went public in 2020. Their focus is on addressing underlying causes, not just symptoms.

business area logo Core Business Areas

  • Rare Disease Therapeutics: Inozyme focuses on developing therapies targeting ENPP1 and NT5E deficiencies, which lead to serious metabolic and cardiovascular complications.

leadership logo Leadership and Structure

The leadership team is composed of experienced pharmaceutical executives and scientists. The organizational structure is typical of a clinical-stage biotech company, with departments focused on research, development, clinical trials, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • INZ-701: INZ-701 is a recombinant human ENPP1 enzyme replacement therapy in clinical development for the treatment of ENPP1 deficiency, including Generalized Arterial Calcification of Infancy (GACI) and autosomal recessive hypophosphatemic rickets type 2 (ARHR2). Since this is a new market with no established players for these specific deficiencies, market share is not yet established. Competitors for GACI treatment include symptomatic treatments or experimental therapies.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is competitive and heavily regulated. The rare disease therapeutics market is growing, driven by increased awareness, orphan drug designations, and unmet medical needs.

Positioning

Inozyme Pharma is positioned as a leader in developing therapies for ENPP1 deficiency. Its competitive advantage lies in its proprietary enzyme replacement therapy and focus on addressing the underlying cause of the disease.

Total Addressable Market (TAM)

The estimated TAM for ENPP1 deficiency related diseases is substantial given the rare nature of the condition. Inozyme is positioned to capture a significant portion of this market if INZ-701 proves effective and receives regulatory approval. TAM estimates are dependent on prevalence and pricing strategies.

Upturn SWOT Analysis

Strengths

  • Novel therapeutic approach
  • Strong intellectual property portfolio
  • Experienced management team
  • Focus on unmet medical needs
  • Orphan drug designation for INZ-701

Weaknesses

  • Single clinical-stage product (INZ-701)
  • High cash burn rate
  • Reliance on successful clinical trial outcomes
  • Lack of established revenue streams
  • Limited commercial infrastructure

Opportunities

  • Expansion of INZ-701 to additional indications
  • Partnerships with larger pharmaceutical companies
  • Acquisition by a larger pharmaceutical company
  • Positive clinical trial results for INZ-701
  • Increased awareness of ENPP1 deficiency

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from other therapies
  • Funding challenges
  • Patent disputes

Competitors and Market Share

competitor logo Key Competitors

  • None listed since INZY focuses on ENPP1 deficiency, with no directly competing therapies currently approved.

Competitive Landscape

Since no competing therapies exist, Inozyme holds the competitive advantage with INZ-701 in the rare disease space of ENPP1 deficiency. This advantage is dependent on successful clinical trials.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is primarily related to R&D spending and clinical trial progress.

Future Projections: Future growth is dependent on the successful development and commercialization of INZ-701. Analyst estimates are based on clinical trial results and market potential. Refer to analyst reports for projections.

Recent Initiatives: Recent initiatives include advancing INZ-701 through clinical trials and seeking regulatory approvals.

Summary

Inozyme Pharma is a clinical-stage biopharmaceutical company focused on rare diseases. Its strength lies in its innovative approach to treating ENPP1 deficiency with INZ-701. However, it faces risks associated with clinical trial outcomes and funding. Successful clinical trials and strategic partnerships are crucial for its growth. Regulatory hurdles pose a continuous challenge.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Inozyme Pharma's website
  • SEC filings
  • Analyst reports
  • Industry publications

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Data may be outdated and subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Inozyme Pharma Inc

Exchange NASDAQ
Headquaters Boston, MA, United States
IPO Launch date 2020-07-24
CEO & Chairman Dr. Douglas A. Treco Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 67
Full time employees 67

Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.